- 21st Century Cures Act nears finish line #CuresNow
- Amicus and Nivalis greet the week with setbacks $NVLS $FOLD
- Arrowhead hits "Ctrl-Alt-Delete" on RNAi pipeine $ARWR
- Inciteful conversations on trading biotech stocks, in light of so many bad news "blowups"
- Drug pricing remains front and center at #ForbesHealth and elsewhere $MYL
- Bluebird Bio warms up the crowd with pre-ASH myeloma data $BLUE
- American Society of Hematology (#ASH16) Highlights
Continue on to Biotech Tweets of the Week (December 5, 2016)